SCHEMBL18163887

SCHEMBL18163887

COc1ccc2nc3cc(Cl)ccc3c(NCCCCCNCCCCCNc3c4ccc(Cl)cc4nc4ccc(OC)cc34)c2c1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.78
MBNL1 Q9NR56 1/20 0.75
MEN1 O00255 2/20 0.73
KMT2A Q03164 2/20 0.73
TDP1 Q9NUW8 2/20 0.73
GSR P00390 7/20 0.68
KDM4E B2RXH2 2/20 0.57
PHLPP2 Q6ZVD8 1/20 0.56
CYP19A1 P11511 1/20 0.56
USP2 O75604 2/20 0.56
TP53 P04637 2/20 0.56
CYP3A4 P08684 2/20 0.56
CASP1 P29466 2/20 0.56
CASP7 P55210 2/20 0.56
HBB P68871 2/20 0.56
HSD17B10 Q99714 2/20 0.56
NPC1 O15118 1/20 0.56
PRNP P04156 1/20 0.56
CHRM2 P08172 1/20 0.56
CHRM4 P08173 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18163881 1.00 ADORA2A (0.78) ADORA2AMBNL1MEN1KMT2ATDP1
SCHEMBL18163854 1.00 ADORA2A (0.78) ADORA2AMBNL1MEN1KMT2ATDP1
SCHEMBL18163882 1.00 ADORA2A (0.78) ADORA2AMBNL1MEN1KMT2ATDP1
SCHEMBL18163846 1.00 ADORA2A (0.78) ADORA2AMBNL1MEN1KMT2ATDP1
SCHEMBL18163852 0.99 ADORA2A (0.80) ADORA2AMBNL1MEN1KMT2ATDP1
Acridine Dimer SCHEMBL31329233 0.98 ADORA2A (0.78) ADORA2AMBNL1MEN1KMT2ATDP1
SCHEMBL12057934 0.98 ADORA2A (0.78) ADORA2AMBNL1MEN1KMT2ATDP1
Acridine Dimer SCHEMBL31494050 0.98 ADORA2A (0.78) ADORA2AMBNL1MEN1KMT2ATDP1
SCHEMBL18163841 0.96 ADORA2A (0.80) ADORA2AMBNL1MEN1KMT2ATDP1
SCHEMBL20087027 0.96 MBNL1 (0.80) ADORA2AMBNL1MEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210070712-A1 Dimeric Quinacrine Derivatives As Autophagy Inhibitors For Cancer Therapy NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-03-11 US disclosed
EP-3283463-B1 DIMERIC QUINACRINE DERIVATIVES AS AUTOPHAGY INHIBITORS FOR CANCER THERAPY UNIV PENNSYLVANIA (US) 2021-01-20 EP disclosed
US-10774047-B2 Dimeric quinacrine derivatives as autophagy inhibitors for cancer therapy THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2020-09-15 US disclosed
US-20180111904-A1 DIMERIC QUINACRINE DERIVATIVES AS AUTOPHAGY INHIBITORS FOR CANCER THERAPY THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 2018-04-26 US disclosed
US-20180111904-A1 DIMERIC QUINACRINE DERIVATIVES AS AUTOPHAGY INHIBITORS FOR CANCER THERAPY THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 2018-04-26 US disclosed
WO-2016168721-A1 DIMERIC QUINACRINE DERIVATIVES AS AUTOPHAGY INHIBITORS FOR CANCER THERAPY THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2016-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10774047-B2 Dimeric quinacrine derivatives as autophagy inhibitors for cancer therapy ATG7, BECN1, SQSTM1 ADORA2A 1315/4885MBNL1 3437/4885MEN1 3124/4885
US-20210070712-A1 Dimeric Quinacrine Derivatives As Autophagy Inhibitors For Cancer Therapy ATG7, BECN1, SQSTM1 ADORA2A 1315/4885MBNL1 3437/4885MEN1 3124/4885
US-20180111904-A1 DIMERIC QUINACRINE DERIVATIVES AS AUTOPHAGY INHIBITORS FOR CANCER THERAPY ATG7, BECN1, SQSTM1 ADORA2A 1315/4885MBNL1 3437/4885MEN1 3124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.